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Dr Jerry R. Youkey (Greenville, SC). Over the course of my
15-year journey to the dark side of medicine, I have progressively
become a closet cynic. It has finally become impossible for me to
face the conundrums of our nonsystem of health care without
eagerly anticipating the irreverent monthly editorials of David
Cossman in the “General Surgery News.” It is from that perspec-
tive that I commend Martin, Hupp, and Hanson for their work
presented today. It is refreshing to witness some of our colleagues
initiating a public health program for the benefit of their commu-
nity. My hat is off to you. I also want to thank you for providing me
with your manuscript for review.
I have three general areas of comment, concern, and question
related to your presentation and to your manuscript. These involve
the presentation of your data, your financial analysis, and your lack
of recommendations.
In regards to your data presentation, I find it confusing at best.
Your apparently arbitrary designation of subcritical vascular labo-
ratory results into significant and critical categories in Tables IV
and V is confounding. Significant for what? Critical to whom?
Further, it is completely at odds with the fact that you chose more
traditional values for following day notification of primary care
physicians of truly critical results. I encourage you to change your
end points to laboratory results showing truly critical disease, that
is, carotid stenosis exceeding 80%, aneurysm exceeding 5 cm, and
ABI of less than 0.3, and laboratory results consistent with systemic
noncritical atherosclerosis warranting patient awareness, educa-
tion, and risk reduction.
If you do this, I suspect that statistical analysis of your data will
not support screening of the vast majority of these patients for
critical disease. It is also likely to show that a single limited study for
screening will identify the majority of patients with systemic non-
critical atherosclerosis. Since your data presentation does not allow
identification of the single best test to identify subcritical disease
indicative of systemic atherosclerosis, it is impossible to tell if this is
correct. Have you any insight into an analysis of your data based
upon this hypothesis?
Although I realize that your statements regarding financial
information were largely an after thought, they have given me
limited but specific concerns. First, it is misleading to speak of the
financial benefit of revenues. Groceries and mortgages are paid for
with margin, which brings me to my second concern. I am quite
provide an indication of the presence of subclinical atheroscleroticskeptical of your statement that once the program was established,
the cost of screening was about $25 per patient. Does that figure
include all overhead costs such as lease and upkeep of space,
liability insurances, interpretation fees, equipment depreciation,
office personnel, and so forth? This is an important disclosure for
all of us, as you may well establish with this publication a new
global multitest vascular laboratory reimbursement benchmark for
CMS and private payers across the country.
In closing, I must confess disappoint with your failure to
provide recommendations regarding screening. I was hopeful that
you would have analyzed your data and suggested an algorithm to
identify which patients would benefit from what kind of screening.
I can only surmise that either you plan to carefully follow your
patients to show that long-term compliance with risk reduction
consequent to your efforts will show efficacy of your program
through reduction of morbid cardiovascular events or that you
concluded that no screening could be justified from your data.
Could you please clarify which, if either, of these suppositions is
correct? Again, I commend the authors for their efforts and wish
them success with their foundation-supported cardiovascular
screening program.
Dr Jon A. Hupp: I would like to thank Dr Youkey for
reviewing our manuscript and for his comments. Our definitions
regarding intermediate and severe disease are somewhat arbitrary.
The definition of intermediate disease, having an AAA of at least 3
cm or a carotid stenosis of at least 40% or an ABI of 0.7, would
typically be a patient that deserves follow-up on a yearly basis and
the severe disease level reflects individuals who need intervention
or closer follow-up. We purposely did not make recommendations
regarding who should be screened. One of our goals with Dare to
C.A.R.E. was to be liberal regarding screening criteria such that
we, and others, could look at the data and decide on appropriate
screening criteria based on available resources and desired disease
detection rates (Table V). We certainly want to find silent disease,
but are also were interested in patient education and increased
awareness. We have not attempted to identify any single best test
for systemic atherosclerosis. Future plans do include a patient
follow-up survey to assess patient risk reduction and compliance.
Subgroup analysis of risk factors and disease detection is also
ongoing.INVITED COMMENTARYRuth L. Bush, Temple, Tex
The American Heart Association has estimated that 8 to 12
million Americans are afflicted with peripheral arterial disease
(PAD) and that nearly 75% of PAD patients are asymptomatic.1
We, as vascular specialists, know all to well that the presence of
PAD is associated with an increased risk of cardiovascular morbid-
ity and mortality and that improvements in risk-factor profiles with
behavior modification and pharmacotherapy can decrease the ad-
verse outcomes of stroke, myocardial infarction, and limb loss. The
key issue is the identification of persons at risk before symptomatic
or critical disease becomes present. For that reason, unrecognized
PAD constitutes an enormous public health problem with the
potential for serious, if not fatal, consequences.
Many health organizations, including many professional vas-
cular societies as well as governmental agencies, have recognized
the importance of early screening and thus have joined groups such
as The Peripheral Arterial Disease Coalition to improve both
public and health professional awareness about the disease. It is
well known that a simple ankle-brachial index measurement maydisease, therefore identifying patients who warrant aggressive ed-
ucation and risk-factor management.
As an example, the PAD Awareness, Risk, and Treatment:
New Resources for Survival (PARTNERS) program, a multicenter,
cross-sectional study conducted at 27 sites in 25 cities and 350
primary care practices throughout the United States (US), dem-
onstrated a prevalence of PAD in 29% of patients screened in a
primary care setting, only 11% of whom had classic symptoms of
claudication.2 Furthermore, many persons had been previously
undiagnosed, and as a result of this unawareness, the rate of
intensive treatment for risk factors was low. In addition in this
study, screening tests discovered patients who also, not uncom-
monly, had concomitant cardiac, cerebrovascular, or abdominal
aortic aneurysmal disease.
Martin and colleagues have taken community PAD screening
programs to a new level and have established a new standard to
which all should be upheld. In their unique Dare to C.A.R.E.
program, they have successfully developed a screening program
which include noninvasive testing for vascular disease, glucose and
